Travere Therapeutics reported a Filspari beat, showing strong Q2 results and growth potential, which was noted by Wedbush and PSFs.
3 reports, 1 independent
Updated Sep 19
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Travere Therapeutics reported a Filspari beat, showing strong Q2 results and growth potential, which was noted by Wedbush and PSFs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Wedbush Securities
US financial services and investment firm
Nothing else this week.
Coverage
Newest first; wire copies grouped- TipRanksTravere Therapeutics price target raised to $32 from $30 at Wedbush Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the shares.